Navigation Links
OHSU Doernbecher Children's Hospital conducts second phase of landmark Batten study
Date:10/29/2010

PORTLAND, Ore. Oregon Health & Science University Doernbecher Children's Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants and children.

The Phase Ib trial, sponsored by StemCells, Inc., is designed to further assess the safety and preliminary effectiveness of StemCells' HuCNS-SC as a potential treatment for NCL, also referred to as Batten disease. This second trial is expected to enroll six children whose NCL is less advanced than those enrolled in the initial Phase I trial, also carried out at OHSU Doernbecher, and, in addition to safety, is also designed to evaluate the impact of HuCNS-SC on disease progression.

"The hard work of testing neural stem cells for their safety and effectiveness in clinical use began here at OHSU Doernbecher Children's Hospital. We are very pleased to carry on this important effort with a second major trial. Our great hope is that this work will eventually yield significant benefits for patients who suffer from devastating nervous system diseases," said Nathan Selden, M.D., Ph.D., FACS, FAAP, Campagna Professor of Pediatric Neurosurgery and head of the Division of Pediatric Neurological Surgery at OHSU Doernbecher Children's Hospital, OHSU School of Medicine.

Selden was co-principal investigator on the groundbreaking initial Phase I trial and will lead the Ib study.

The initial trial was the first-ever FDA-authorized clinical trial of purified human neural stem cells as a potential therapeutic agent. Begun in March 2006, its aim was to test the safety and preliminary efficacy of transplanting HuCNS-SC in six children with advanced stages of NCL. Once transplanted, the children were followed for 12 months. Dat
'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Childrens Hospital LA discovers growth factor essential to epicardial cell function
2. Malnutrition increases risk of prolonged hospital stay
3. McLean Hospital researchers awarded $1.9 9 million grant for stem cell, blood research
4. Vitamin C rapidly improves emotional state of acutely hospitalized patients, say LDI researchers
5. Opioid use to relieve pain and suffering at end of life is safe in hospital-at-home setting
6. Researchers at Childrens Hospital Los Angeles find diet-induced obesity accelerates leukemia
7. Memorial Hospital Selects DigitalPersona Pro to Enhance HIPAA Security
8. Texas Childrens Hospital vaccine experts present 4 studies
9. Nude-colored hospital gowns could help doctors better detect hard-to-see symptoms
10. Temple University Hospital and PASNAP Negotiations Break Off: Talks to Resume Later Today
11. Researchers find Clostridium difficile is more common than MRSA in southeast community hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... release is available in German . ... that show a huge improvement in the light absorption ... This has been achieved by applying atomic layer coating. ... high sensitivity light response such as high efficiency solar ...
... in Earth,s climate from more than 100,000 years ago indicates ... previously thought and may be a good analog for future ... temperatures rise. The research findings also indicate that ... contributed more to sea-level rise at that time than melting ...
... The iconic salt marshes of the famous summer retreat ... the most popular recreational areas. The erosion is a ... Great Depression-era ditches constructed by Works Progress Administration (WPA) ... ecological cause and effect is described by Tyler Coverdale ...
Cached Biology News:Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 2Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 3Analysis of Greenland ice cores adds to historical record and provide glimpse into climate's future 4Depression-era drainage ditches emerge as sleeping threat to Cape Cod salt marshes 2Depression-era drainage ditches emerge as sleeping threat to Cape Cod salt marshes 3Depression-era drainage ditches emerge as sleeping threat to Cape Cod salt marshes 4
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... DIEGO , April 16, 2015  AnaptysBio, ... development of therapeutic antibodies, today announced the ... antibody program into IND-enabling studies. The Company,s ... novel treatment for generalized pustular psoriasis (GPP), ... unmet medical need. ANB019 is wholly owned within ...
(Date:4/16/2015)... Switzerland , April 16, ... part of Debiopharm Group ™ , a Swiss-based ... target unmet medical needs as well as ... on the investigational compounds Debio 1143 (SMAC mimetic) ... presented at the 2015 Annual meeting of ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... CARLOS, Calif., Dec. 2 SleepQuest is proud to ... Joint Commission on the,Accreditation of Health Care Organizations (JCAHO) ... and safety. , ... of,national standards by The Joint Commission,s home care service ...
... Martek Biosciences Corporation (Nasdaq: MATK ) announced that it ... year 2008 on December 11, 2008, at approximately 4:00 p.m. Eastern ... will conduct a conference call to discuss these results with investors. ... webcast by visiting Martek,s web site at http://investors.martek.com . , ...
... On Track to File NDA with FDA in Early ... WOODCLIFF LAKE, N.J., Dec. 2 Strativa Pharmaceuticals, the ... PRX ) today announced that its development ... pivotal bioequivalence studies for a thin film formulation of ...
Cached Biology Technology:SleepQuest Achieves Coveted Accreditation 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 2Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 3Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film 4
... The Jouan RC Maxi MB (for ... of vacuum concentrator/centrifugal evaporator systems respond to ... for rapid and safe concentration of heat-labile ... with pumps, different of cold traps and ...
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... RC Standard MB (For small quantities of ... samples) of vacuum concentrator/centrifugal evaporator systems respond ... biochemistry for rapid and safe concentration of ... expanded with pumps, different of cold traps ...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: